Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

"With no treatment options currently available for the broad population of patients with secondary progressive multiple sclerosis, tolebrutinib has demonstrated its ability to delay disability by ...

The following is a summary of “Neurofilament heavy chain in secondary progressive multiple sclerosis,” published in the January 2025 issue of Neurology by Angelis et al. Biomarkers are essential for ...

Like benign MS, RRMS can change its course. When RRMS transitions into progressive MS, it’s called secondary progressive MS (SPMS). There are no clear periods of remission in SPMS. People with ...

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

There isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the NHS (SPMS), despite a desperate lack of treatments for this form of the ...

most people have relapsing-remitting MS. Other types include primary progressive MS, secondary progressive MS, and clinically isolated MS. Contact your doctor if you have concerns about MS. They ...

Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) Tolebrutinib is the first and only brain-penetrant ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

“We are excited to announce this breakthrough in understanding how nasal foralumab induces immune modulation in Secondary Progressive MS patients,” said Dr. Tanuja Chitnis, M.D., Principal ...